Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance)

被引:65
作者
Burstein, Harold J. [1 ]
Cirrincione, Constance T. [2 ]
Barry, William T. [1 ]
Chew, Helen K. [4 ]
Tolaney, Sara M. [1 ]
Lake, Diana E. [5 ]
Ma, Cynthia [6 ]
Blackwell, Kimberly L. [3 ]
Winer, Eric P. [1 ]
Hudis, Clifford A. [5 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Univ Calif Davis, Davis, CA 95616 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
关键词
ESTROGEN-RECEPTOR; TYROSINE KINASES; TAMOXIFEN; ANASTROZOLE; RESISTANCE; PATHWAYS; GW572016; SAFETY; ERBB2;
D O I
10.1200/JCO.2014.56.7941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor-positive metastatic breast cancer treated with fulvestrant. Patients and Methods Eligible women had estrogen receptor-positive and/or progesterone receptor-positive tumors, regardless of human epidermal growth factor receptor 2 (HER2) status, and prior aromatase inhibitor treatment. Patients received fulvestrant 500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg or placebo daily. The study planned to accrue 324 patients and was powered for a 50% improvement in PFS with lapatinib from 5 to 7.5 months. Results At the third planned interim analysis, the futility boundary was crossed, and the data and safety monitoring board recommend study closure, having accrued 295 patients. At the final analysis, there was no difference in PFS (hazard ratio [HR] of placebo to lapatinib, 1.04; 95% CI, 0.82 to 1.33; P = .37); median PFS was 4.7 months for fulvestrant plus lapatinib versus 3.8 months for fulvestrant plus placebo. There was no difference in overall survival (OS) (HR, 0.91; 95% CI, 0.68 to 1.21; P = .25). For HER2-normal tumors, median PFS did not differ by treatment arm (4.1 v 3.8 months). For HER2-positive tumors, lapatinib was associated with longer median PFS (5.9 v 3.3 months), but the differential treatment effect by HER2 status was not significant (P = .53). The most frequent toxicities were diarrhea, fatigue, and rash associated with lapatinib. Conclusion Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic. (C) 2014 by American Society of Clinical Oncology
引用
收藏
页码:3959 / U247
页数:10
相关论文
共 32 条
[21]   MULTIPLE TESTING PROCEDURE FOR CLINICAL-TRIALS [J].
OBRIEN, PC ;
FLEMING, TR .
BIOMETRICS, 1979, 35 (03) :549-556
[22]  
Osborne CK, 2005, CLIN CANCER RES, V11, p865S
[23]   Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors:: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) [J].
Perey, L. ;
Paridaens, R. ;
Hawle, H. ;
Zaman, K. ;
Nole, F. ;
Wildiers, H. ;
Fiche, M. ;
Dietrich, D. ;
Clement, P. ;
Koeberle, D. ;
Goldhirsch, A. ;
Thuerlimann, B. .
ANNALS OF ONCOLOGY, 2007, 18 (01) :64-69
[24]   Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) [J].
Pritchard, Kathleen I. ;
Rolski, Janusz ;
Papai, Zsuzsanna ;
Mauriac, Louis ;
Cardoso, Fatima ;
Chang, Jose ;
Panasci, Lawrence ;
Ianuli, Carmen ;
Kahan, Zsuzsanna ;
Fukase, Kenjiro ;
Lindemann, Justin P. O. ;
Macpherson, Merran P. ;
Neven, Patrick .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) :453-461
[25]   Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials [J].
Robertson, JFR ;
Osborne, CK ;
Howell, A ;
Jones, SE ;
Mauriac, L ;
Ellis, M ;
Kleeberg, UR ;
Come, SE ;
Vergote, I ;
Gertler, S ;
Buzdar, A ;
Webster, A ;
Morris, C .
CANCER, 2003, 98 (02) :229-238
[26]   Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study [J].
Robertson, John F. R. ;
Llombart-Cussac, Antonio ;
Rolski, Janusz ;
Feltl, David ;
Dewar, John ;
Macpherson, Euan ;
Lindemann, Justin ;
Ellis, Matthew J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4530-4535
[27]  
Rusnak DW, 2001, CANCER RES, V61, P7196
[28]   Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen [J].
Sabnis, Gauri ;
Schayowitz, Adam ;
Goloubeva, Olga ;
Macedo, Luciana ;
Brodie, Angela .
CANCER RESEARCH, 2009, 69 (04) :1416-1428
[29]   Endocrine Therapy for Advanced/Metastatic Breast Cancer [J].
Schiavon, Gaia ;
Smith, Ian E. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (04) :715-+
[30]   Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer [J].
Shou, J ;
Massarweh, S ;
Osborne, CK ;
Wakeling, AE ;
Ali, S ;
Weiss, H ;
Schiff, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (12) :926-935